Understand the question
We review the literature, challenge assumptions and identify the main scientific risk.
Contact us Menu
Radiopharmaceutical science Biotechnology startup & expert consultancy
From molecular design
to in vivo evidence.
NuclearPharm supports radiopharmaceutical programmes for imaging and therapy with integrated radiochemistry, analytical development, preclinical studies and scientific consulting.
How we work
Your science stays at the centre.
We take time to understand the molecule, the evidence and the decision ahead. That depth helps us design useful studies, solve problems early and support stronger research.
Design useful evidence
We choose methods that answer the immediate question and remain valuable at the next stage.
Connect the disciplines
We interpret chemistry, biology and nuclear medicine as one body of evidence.
Stay involved
We support discussion, troubleshooting and the decisions that follow each result.
We treat every project as a scientific collaboration.
Expect open communication, careful work and direct access to the people doing the science.
Scientific consulting
Clear thinking at every stage.
We do more than perform experiments. We review the literature, assess risk, design studies, analyse data and help decide what should happen next.
Understand
The molecule, literature and development context
Plan
The question, risk and evidence needed
Perform
The study with fit-for-purpose methods
Analyse
The results across scientific disciplines
Recommend
A clear and practical next step
Capabilities
Support across the development pathway.
Work with one scientific team from medicinal chemistry and radiochemistry to biological evaluation, imaging, automation and higher-activity studies.
Equipment quality
Calibrated instruments and planned maintenance.
Our equipment—from pipettes and balances to chromatography systems, radiodetectors and UPLC-MS—is routinely calibrated and maintained to support consistent work.
01
Scientific strategy & study design
Start with the decision the programme needs to make, then design the evidence to answer it.
What we do
- Literature and feasibility review
- Risk mapping and development planning
- Study design and data interpretation
02
Medicinal chemistry
Develop ligands, precursors and reference compounds with later radiolabelling in mind.
What we do
- New compound and precursor synthesis
- Route and reaction optimisation
- Purification and reference-standard preparation
Equipment & methods
Preparative HPLCFlash chromatographySemi-preparative purification
03
Chemical characterisation
Confirm structure, identity and purity by bringing complementary analytical techniques together.
What we do
- Structural and molecular-mass confirmation
- Identity, purity and reference-standard assessment
- Interpretation across orthogonal datasets
Equipment & methods
04
Radiochemistry
Develop and optimise radiolabelling chemistry for diagnostic and therapeutic programmes.
What we do
- Radiolabelling and purification development
- Reaction-condition optimisation
- Broad diagnostic and therapeutic radionuclide experience
Equipment & methods
05
Formulation & stability
Prepare the radioactive product for its intended study and understand how it performs over time.
What we do
- Formulation development
- Stability in buffer, plasma and serum
- Osmolality, pH and residual-solvent assessment
Equipment & methods
OsmometerGas chromatographypH measurementDose calibrators
06
Analytical development
Build methods for radioactive and non-radioactive samples using complementary separation and detection.
What we do
- TLC, HPLC and UPLC method development
- Radio-HPLC, radio-UPLC-MS and radio-HPLC-MS
- UV, fluorescence and radioactivity detection
Equipment & methods
Autosamplers and column heatersDAD, TUV and fluorescence detectorsRadiodetectors and fraction collectorsWatersElysia-RaytestLabLogic
07
Metabolite & impurity analysis
Investigate what changed, where it came from and whether it matters to the programme.
What we do
- Metabolite profiling in biological matrices
- Impurity and degradation-product investigation
- Radioactivity, optical and MS data correlation
Equipment & methods
Radio-UPLC-MSRadio-HPLC-MSFraction collectionGamma and liquid-scintillation counting
08
In vitro evaluation
Measure how a candidate interacts with its target in real time and under relevant biological conditions.
What we do
- Binding, uptake and kinetic studies
- Internalisation and efflux
- Affinity, competition and cell-based evaluation
Equipment & methods
09
In vivo models & biodistribution
Generate whole-animal and tissue-level evidence to understand targeting, clearance and organ exposure.
What we do
- Tumour models
- Biodistribution studies
- Tissue collection and gamma counting
Equipment & methods
IVC housing and change cabinetGamma and liquid-scintillation counting
10
Imaging & autoradiography
Connect non-invasive imaging with high-resolution ex vivo spatial distribution.
What we do
- PET, SPECT and CT imaging
- Image analysis and anatomical co-registration
- Real-time digital autoradiography
Equipment & methods
11
Automation & sequence development
Translate manual chemistry into controlled, repeatable automated processes.
What we do
- Trasis AllinOne sequence development
- Process optimisation and troubleshooting
- Method transfer and operator support
Equipment & methods
12
Higher-activity translation
Access cyclotron and GMP infrastructure through collaboration when a programme is ready to move beyond laboratory-scale work.
What we do
- Higher-activity fluorine-18 work
- Cyclotron and GMP-environment access
- AllinOne and FASTlab synthesis capability
Equipment & methods
Our research
Our team also develops its own programmes.
Active research keeps us close to the practical decisions, setbacks and refinements that shape radiopharmaceutical development.
Sentinel lymph-node detection
Tumour imaging and therapy
Prostate-cancer imaging and therapy
Infection versus inflammation
Collaborators & support network
Organisations we work with.
Your scientific team
Work directly with our scientists.
Contact
Let’s discuss your programme.
Tell us what you are developing, where the work stands and which decision comes next. You will speak directly with scientists.
Leof. Andrea Siggrou 196Athens 176 71, Greeceantonio.shegani@nuclearpharm.com